Phaseline

Companies › Asher Biotherapeutics

Asher Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
etakafusp alfa (AB248)
CD8+ T cell selective interleukin-2 agonist
IL2Phase 1Solid TumorMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05653882etakafusp alfa (AB248)Phase 1Solid TumorOncologyMay 2027

Targets

IL2 (1)

Companies with the same targets

Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics Coya Therapeutics Synthekine Nektar Therapeutics HCW Biologics Regeneron Pharmaceuticals Salspera Iovance Biotherapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.